Aurobindo Pharma Ltd’s net profit declined marginally by 0.65 per cent to Rs 529 crore in the quarter ended March 31, 2018 compared with Rs 532 crore in the corresponding quarter of previous year.

Total revenue of the Hyderabad-based company, however, increased 11.2 per cent to Rs 4,049 crore (Rs 3,642 crore).

For the full year ended March 31, 2018, revenues grew 9.3 per cent to Rs 16,499.8 crore, while net profit rose 5.3 per cent to Rs 2,423 crore.

Commenting on the company’s performance, N Govindarajan, Managing Director, Aurobindo Pharma, said: “The company has reported a healthy growth in revenues and profitability in FY18, led by improvement in most of the markets.’’

“Aurobindo will continue to ramp up investment in differentiated and speciality product portfolio. Our execution strength and pipeline evolution will drive growth for the future,’’ he added.

Revenue from formulations recorded a growth of 12.4 per cent to Rs 13,533 crore and accounted for 82 per cent of the total revenue. During the fourth quarter, formulations revenue registered a growth of 12.8 per cent to Rs 3,248.6 crore.

Aurobindo had filed 11 Abbreviated New Drug Applications (ANDAs) with the USFDA, including two injectables, during the quarter under review and 47 ANDAs, including 16 injectables, in FY18. It had received final approval for 10 ANDAs in Q4FY18 and 49 ANDAs, including 7 injectables, in the full year under review.

The company had launched seven products, including one injectable, in the fourth quarter and 38 products, including 6 injectables, during the fiscal. As on March 31, 2018, on a cumulative basis, the company had filed 478 ANDAs with USFDA and received approval for 361 ANDAs, including 34 tentative approvals.

Related Topics